Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.